Company Filing History:
Years Active: 2010-2022
Title: Innovations of Robert Kling in Alpha-1-Antitrypsin Purification
Introduction
Robert Kling is an accomplished inventor based in Bourbonnais, IL (US). He has made significant contributions to the field of biochemistry, particularly in the purification of alpha-1-antitrypsin (AAT). With a total of 7 patents to his name, Kling's work has the potential to impact pharmaceutical processes significantly.
Latest Patents
Kling's latest patents focus on methods of treatment using alpha-1-antitrypsin compositions. One of his notable inventions is a streamlined method for purifying AAT from an AAT-containing protein mixture, such as Coh fraction IV precipitate. This innovative method involves destabilizing contaminating proteins by cleaving disulfide bonds with a reducing reagent, such as dithiol, which does not affect AAT. The destabilized proteins are preferentially adsorbed on a solid protein-adsorbing material, eliminating the need for salt as a precipitant. The separation of the solid absorbent from the solution results in a purified AAT solution that is directly suitable for chromatographic purification, without extensive desalting as required in prior art processes. This method provides pharmaceutical-grade AAT in high yield on a commercial scale.
Career Highlights
Robert Kling is currently associated with CSL Behring GmbH, where he continues to innovate in the field of protein purification. His work has been instrumental in advancing methods that enhance the efficiency and effectiveness of AAT purification processes.
Collaborations
Kling has collaborated with notable colleagues, including Scott M Kee and Paul I Cook. Their combined expertise has contributed to the successful development of innovative solutions in the biopharmaceutical industry.
Conclusion
Robert Kling's contributions to the purification of alpha-1-antitrypsin highlight his role as a significant inventor in the biochemistry field. His innovative methods not only improve purification processes but also have the potential to enhance the availability of pharmaceutical-grade AAT.